Analyst Reco. Disc Medicine, Inc.

Equities

IRON

US2546041011

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
31.84 ^USD	+2.68%		+5.99%	-44.88%

May. 09	Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	Apr. 08	MT
Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	Apr. 02	MT
Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating	Apr. 02	MT
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating	Apr. 02	MT
Stifel Adjusts Price Target on Disc Medicine to $71 From $104, Keeps Buy Rating	Apr. 02	MT
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept	Apr. 02	MT
Raymond James Downgrades Disc Medicine to Outperform From Strong Buy, Cuts Price Target to $40 From $75	Apr. 01	MT
Wedbush Raises Disc Medicine Price Target to $84 From $79, Maintains Outperform Rating	Mar. 21	MT
Stifel Adjusts Price Target on Disc Medicine to $104 From $76, Maintains Buy Rating	Mar. 12	MT
Morgan Stanley Downgrades Disc Medicine to Equalweight From Overweight, Raises Price Target to $65 From $56	Dec. 19	MT
HC Wainwright Adjusts Price Target on Disc Medicine Opco to $70 From $66, Keeps Buy Rating	23-08-14	MT
Wedbush Adjusts Disc Medicine Opco Price Target to $79 From $58, Maintains Outperform Rating	23-08-11	MT
BMO Capital Raises Price Target on Disc Medicine to $70 From $40, Maintains Outperform Rating	23-06-12	MT
Morgan Stanley Adjusts Price Target on Disc Medicine to $56 From $37, Maintains Overweight Rating	23-06-12	MT
Raymond James Upgrades Disc Medicine to Strong Buy From Outperform, Adjusts Price Target to $75 From $50	23-06-12	MT
Wedbush Raises Disc Medicine Opco's PT to $58 From $41 After Positive Initial Data From Mid-Stage Trial of Bitopertin, Keeps Outperform Rating	23-06-09	MT
Raymond James Upgrades Disc Medicine to Strong Buy From Outperform, Adjusts Price Target to $75 From $50	23-06-09	MT
HC Wainwright Adjusts Price Target on Disc Medicine Opco to $66 From $55, Reiterates Buy Rating	23-06-09	MT
HC Wainwright Starts Disc Medicine at Buy With $55 Price Target	23-06-07	MT
Raymond James Initiates Disc Medicine Opco at Outperform With $50 Price Target	23-05-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Disc Medicine, Inc.

Equities

IRON

US2546041011

Analyst Reco.

Filters